Abstract
BackgroundRecent studies have suggested that late-outgrowth endothelial progenitor cells (EPCs) derived from human peripheral blood mononuclear cells (hPBMNCs) might have higher angiogenic potential than classically-defined early-outgrowth EPCs (EOCs). However, it still remains unclear which of “so-called” EPC subpopulations defined in a variety of ways has the highest angiogenic potential. Methods and resultsWe classified hPBMNC-derived EPC subpopulations by the time of their emergence in culture. EOCs were defined as attached cells on culture days 3–7. Late-outgrowth EPCs, defined as the cell forming colonies with cobblestone appearance since day 10, were further classified as follows: “moderate”-outgrowth EPCs (MOCs) emerging on days 10–16, “late”-outgrowth EPCs (LOCs) on days 17–23, and “very late”-outgrowth EPCs (VOCs) on days 24–30. Flow cytometry analyses showed the clear differences of hematopoietic/endothelial markers between EOC (CD31+VE-cadherin−CD34−CD14+CD45+) and LOC (CD31+VE-cadherin+CD34+CD14−CD45−). We found that LOCs had the highest proliferation and tube formation capabilities in vitro along with the highest expression of angiogenic genes including KDR and eNOS. To investigate the in vivo therapeutic efficacies, each EPC subpopulation was intravenously transplanted into immunocompromised mice (total 4×105 cells) after unilateral hindlimb ischemia surgery. The LOC-treated mice exhibited significantly-enhanced blood flow recovery (flow ratios of ischemic/non-ischemic leg: 0.99±0.02 [LOC group] versus 0.67±0.07 to 0.78±0.09 [other groups]; P<0.05) and augmented capillary collateral formation in ischemic leg, which were attributable to their direct engraftment into host angiogenic vessels (approximately 10%) and paracrine effects. ConclusionhPBMNC-derived late-outgrowth EPCs emerging on culture days 17–23 are superior to other EPC subpopulations with regard to therapeutic angiogenic potential.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
